Overview of Medicare Part D prescription drug benefit: Potential implications for patients with psychotic disorders

被引:1
|
作者
Rosenberg, Jack A.
机构
[1] Long Isl Univ, Int Drug Informat Ctr, Brooklyn, NY 11201 USA
[2] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY 11201 USA
关键词
costs; economics; healthbenefit programs; laws; pharmacists; prescriptions; psychotherapeutic agents; psychotic disorders;
D O I
10.2146/ajhp060592
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. Medicare Part D prescription drug benefits are reviewed. Potential implications, for patients with psychotic disorders in relation to Medicare Part D are discussed. Summary. The newly created Medicare Part D provides prescription drug benefits to many individuals formerly without prescription benefits and, possibly, lower-cost benefits to those who previously relied on other benefits., Participating prescription plans use a variety of pharmacy management tools to minimize costs while providing benefit plans that meet Part D requirements for composition and coverage. Patients then have the challenge of choosing a prescription drug plan that will best satisfy their prescriptions needs. Conclusion. The rollout of Part D has not been without problems, and although more Medicare participants are receiving prescription drug benefits at a greater savings,there are concerns that Part D may not provide adequate coverage for all patients or for patients requiring certain types of medications, especially some psychotropic medications. Pharmacists have voiced concerns about the Medicare Part D drug plan in regard to both the degree of coverage it provides to enrollees and the difficulty in administering the benefit.
引用
收藏
页码:S18 / S23
页数:6
相关论文
共 50 条
  • [31] The political calculus of a Medicare Prescription Drug benefit
    Lyles, A
    CLINICAL THERAPEUTICS, 2004, 26 (09) : 1516 - 1517
  • [32] Consumer rights and the medicare prescription drug benefit
    Hayes, R
    GERONTOLOGIST, 2004, 44 : 383 - 383
  • [33] Perverse incentives in the medicare prescription drug benefit
    McAdams, David
    Schwarz, Michael
    INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING, 2007, 44 (02) : 157 - 166
  • [34] Confusing Inequitable Medicare Prescription Drug Benefit
    Gail E. Shearer
    Journal of General Internal Medicine, 2007, 22 : 286 - 288
  • [35] The Case for Restructuring the Medicare Prescription Drug Benefit
    Frakt, Austin
    Miller, Mark
    HEALTH SERVICES RESEARCH, 2018, 53 (06) : 4132 - 4137
  • [36] The medicare part D drug program: Making the most of the benefit
    Utz, Sharon W.
    FAMILY & COMMUNITY HEALTH, 2008, 31 (04) : 350 - 351
  • [37] Part "D" for "defective" - The Medicare drug benefit chaos.
    Avorn, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (13): : 1339 - 1341
  • [38] Cost Minimization of Medicare Part D Prescription Drug Plan Expenditures
    Patel, Rajul A.
    Lipton, Helene Levens
    Cutler, Timothy W.
    Smith, Amanda R.
    Tsunoda, Shirley M.
    Stebbins, Marilyn R.
    AMERICAN JOURNAL OF MANAGED CARE, 2009, 15 (08): : 545 - 553
  • [39] Patient Experiences in Selecting a Medicare Part D Prescription Drug Plan
    Stults, Cheryl D.
    Baskin, Alison S.
    Bundorf, M. Kate
    Tai-Seale, Ming
    JOURNAL OF PATIENT EXPERIENCE, 2018, 5 (02): : 147 - 152
  • [40] SOURCES OF REGIONAL VARIATION IN MEDICARE PART D PRESCRIPTION DRUG SPENDING
    Donohue, J. M.
    Morden, N.
    Gellad, W. F.
    Bynum, J.
    Hanlon, J. T.
    Zhou, W.
    Skinner, J.
    GERONTOLOGIST, 2011, 51 : 180 - 180